@entity22398 has no beneficial effects in the treatment of chronic XXXX .

@entity1 @entity22398 @entity565 @entity8610 @entity4352 @entity20512 @entity110
BACKGROUND: Leukotriene receptor antagonists have shown some efficacy in t he treatment of @entity565 . Injection of LTC4, LTD4 and LTE4 into the skin leads to a weal-and-flare reaction, suggesting an involvement of leukotrienes in the pathogenesis of @entity110 . Indeed, various reports have indicated a beneficial effect for leukotriene receptor antagonists in @entity1 with chronic @entity110 . OBJECTIVE: To determine the therapeutic effect of the leukotriene receptor antagonist @entity22398 in @entity1 with chronic @entity110 . METHODS: The study was a double-blind, placebo-controlled, cross-over study lasting for 12 weeks. Fifty-two @entity1 with chronic @entity110 were investigated at a university hospital. The @entity1 were randomized to receive 20 mg @entity22398 b.i.d. or placebo and cross-over was scheduled after 6 weeks. The efficacy of the treatment was evaluated by a daily symptom score, six physical examinations, the requirement of rescue @entity8610 ( @entity20512 ) and an overall assessment by the @entity1 andthe investigating physician. RESULTS: Forty-six @entity1 completed the study: @entity22398 was well tolerated without alteration of the investigated laboratory parameters. In comparison with placebo, treatment with @entity22398 resulted in no significant positive effect for any of the efficacy measures. Moreover, we were unable to identify any subgroup of @entity1 with chronic @entity110 responding with a therapeutic benefit. CONCLUSIONS: The @entity4352 receptor antagonist @entity22398 does not provide a significant therapeutic benefit at a dose of 20 mg b.i.d. in @entity1 with chronic @entity110 .
